Publications by authors named "D Dorr"
Introduction: The 2024 Voice AI Symposium, hosted by the Bridge2AI-Voice Consortium in Tampa, FL, featured two keynote speeches that addressed the intersection of voice AI, healthcare, ethics, and law. Dr. Rupal Patel and Dr.
View Article and Find Full Text PDFThe transcription factor CCAAT enhancer binding protein alpha (C/EBPα) is a master regulator of myelopoiesis. encodes a long (p42) and a truncated (p30) protein isoform from a single mRNA. Mutations that abnormally enhance expression of p30 are associated with acute myelogenous leukemia (AML).
View Article and Find Full Text PDFArticle Synopsis
- The 2024 Voice AI Symposium gathered experts to discuss advancements in voice biomarkers and AI applications in healthcare through five educational workshops.
- Topics covered included international standardization, real-world AI deployment, assistive technologies, best practices for data collection, and deep learning applications in voice analysis.
- Key outcomes emphasized the need for unified standards, challenges in practical AI deployment, ethical considerations in data collection, and innovations in managing voice disorders using AI technology.
Background: The impact of multimorbidity (≥ 2 chronic diseases) on the well-being of older adults is substantial but variable. The burden of multimorbidity varies by the number and kinds of conditions, and timing of onset. The impact varies by age, race, ethnicity, socioeconomic status, and health indicators.
View Article and Find Full Text PDFArticle Synopsis
- This study compares the cardiovascular effectiveness of different second-line antihyperglycemic agents (SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas) in patients with type 2 diabetes and cardiovascular disease.
- Using data from over 1.4 million patients across multiple databases, the researchers analyzed the risk of major adverse cardiovascular events (MACE) over a follow-up period of several years.
- Results indicated that SGLT2 inhibitors and GLP-1 receptor agonists had significantly lower risks of MACE compared to DPP-4 inhibitors and sulfonylureas, pointing to their potential superiority as treatment options for